The company reported a 16.7% year-over-year increase in net revenues for fiscal 2025 but widened its loss per share.
Pomdoctor Limited reported FY 2025 net revenues of $57.2 million, up 16.7% from the prior year, driven by higher sales volumes. Gross profit rose 9.6% to $7.5 million, though gross margin narrowed to 13.1% from 13.9%.
In fiscal 2024, net revenues stood at $49.7 million, with gross profit at $6.8 million. The company’s loss per share widened slightly to $3.14 from $3.06 in the previous year.
No immediate market reaction was disclosed in the release.